OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
CSCI
COSCIENS Biopharma Inc
Ordinary Shares
3.68
0.11
3.08%
Delayed (15 Min) Trade Data: 03:59pm 06/16/2025
Business Description
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.
Aeterna Zentaris is dedicated to the development of therapeutic assets ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001113423
Fiscal Year End
12/31
Company Officers & Contacts
Gilles Gagnon
President, CEO
Jurgen Engel
COO
Mario Maradis
Secretary
Board of Directors
Not available
Other Company Insiders
Not available
Service Providers
Not available
Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
CA
Employees
Not Available
Shell
No
Products and Services
Not available
Company Facilities
Not available
Company Notes
Formerly=AEterna Zentaris Inc. until 8-2024
Formerly=AEterna Laboratories Inc. until 6-04
Loading...
Symbol
OTCM
Last
51.00
Change
-0.15 (-0.29%)
Bid
50.25
Ask
51.40
Volume
8063
Time
15:57
